$9.66
5.48% day before yesterday
NYSE, Dec 27, 10:00 pm CET
ISIN
US37611X1000
Symbol
DNA

Ginkgo Bioworks Stock price

$9.66
+1.40 16.95% 1M
-2.71 21.90% 6M
-57.94 85.71% YTD
-61.14 86.36% 1Y
-379.54 97.52% 3Y
-395.14 97.61% 5Y
-395.14 97.61% 10Y
NYSE, Closing price Fri, Dec 27 2024
-0.56 5.48%
ISIN
US37611X1000
Symbol
DNA
Sector

Key metrics

Market capitalization $526.27m
Enterprise Value $352.79m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.62
P/S ratio (TTM) P/S ratio 2.41
P/B ratio (TTM) P/B ratio 0.61
Revenue growth (TTM) Revenue growth -30.81%
Revenue (TTM) Revenue $217.95m
EBIT (operating result TTM) EBIT $-515.36m
Free Cash Flow (TTM) Free Cash Flow $-387.26m
Cash position $619.07m
EPS (TTM) EPS $-12.90
P/E forward negative
P/S forward 2.31
EV/Sales forward 1.55
Short interest 21.55%
Show more

Is Ginkgo Bioworks a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Ginkgo Bioworks Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Ginkgo Bioworks forecast:

1x Buy
17%
1x Hold
17%
4x Sell
67%

Analyst Opinions

6 Analysts have issued a Ginkgo Bioworks forecast:

Buy
17%
Hold
17%
Sell
67%

Financial data from Ginkgo Bioworks

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
218 218
31% 31%
100%
- Direct Costs 98 98
43% 43%
45%
120 120
16% 16%
55%
- Selling and Administrative Expenses 167 167
34% 34%
77%
- Research and Development Expense 408 408
31% 31%
187%
-455 -455
35% 35%
-209%
- Depreciation and Amortization 60 60
48% 48%
28%
EBIT (Operating Income) EBIT -515 -515
37% 37%
-236%
Net Profit -651 -651
24% 24%
-299%

In millions USD.

Don't miss a Thing! We will send you all news about Ginkgo Bioworks directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ginkgo Bioworks Stock News

Neutral
PRNewsWire
12 days ago
Ginkgo Bioworks to apply its mammalian cell engineering expertise to develop new cell-based systems for treating and monitoring endocrine disorders BOSTON , Dec. 17, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a subcontract of up to $9.4 million awarded in partnership with Carnegie Mellon Universi...
Neutral
Seeking Alpha
about one month ago
Ginkgo Bioworks reported solid Q3 results, but underlying performance was weaker than the financials suggest after accounting for meaningless non-cash revenue. Ginkgo's new business model focuses on upfront value creation and solutions which reduce friction in the customer acquisition process. While Ginkgo continues to introduce new tools and is landing customers with these products, it is too ...
Neutral
Seeking Alpha
about 2 months ago
Ginkgo Bioworks reported mixed Q3 results, with a $45 million one-time revenue boost masking underlying revenue growth issues. Despite cost cutting efforts, Ginkgo continues to report large losses, and $325 million of cash was burned in the first nine months of 2023. The balance sheet is weakening, and long-term revenue estimates have continued to move lower.
More Ginkgo Bioworks News

Company Profile

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Head office United States
CEO Jason Kelly
Employees 1,218
Founded 2008
Website www.ginkgobioworks.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today